Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Data: The market value of AI tokens has dropped to the range of 50 billion US dollars, a decrease of about 28% from the peak at the beginning of December

Data: The market value of AI tokens has dropped to the range of 50 billion US dollars, a decrease of about 28% from the peak at the beginning of December

Bitget2024/12/28 20:49

According to Cointelegraph, data from CoinMarketCap shows that the market capitalization of artificial intelligence cryptocurrencies has reached $50.5 billion, a drop of about 28% from its peak of $70.4 billion on December 7th. In addition, the cumulative trading volume around AI tokens has also declined, falling nearly 11% in the past month, indicating a decrease in traders' interest in AI cryptocurrencies. However, more and more analysts predict that by 2025 there will be an altcoin season where Bitcoin's profits may flow into small-cap cryptocurrencies including AI tokens.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss